RhumbLine Advisers
ALXO icon

RhumbLine Advisers’s ALX Oncology ALXO Stock Holding History

RhumbLine Advisers’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,302
Closed -$28.8K – 4145
2025
Q1 		$28.8K Buy
46,302
+3,786
+9% +$4.54K ﹤0.01% 3679
2024
Q4 		$71K Buy
42,516
+405
+1% +$623 ﹤0.01% 3578
2024
Q3 		$76.6K Sell
42,111
-13,109
-24% -$48.7K ﹤0.01% 3586
2024
Q2 		$333K Buy
55,220
+5,360
+11% +$65.9K ﹤0.01% 2938
2024
Q1 		$556K Buy
49,860
+1,706
+4% +$24K ﹤0.01% 2608
2023
Q4 		$717K Sell
48,154
-2,803
-6% -$26.6K ﹤0.01% 2458
2023
Q3 		$245K Buy
50,957
+607
+1% +$3.29K ﹤0.01% 3044
2023
Q2 		$378K Buy
50,350
+11,443
+29% +$74.9K ﹤0.01% 2869
2023
Q1 		$176K Buy
38,907
+930
+2% +$7.04K ﹤0.01% 2760
2022
Q4 		$428K Buy
37,977
+5,467
+17% +$61.4K ﹤0.01% 2540
2022
Q3 		$311K Buy
32,510
+3,523
+12% +$41.1K ﹤0.01% 2712
2022
Q2 		$235K Buy
28,987
+10,614
+58% +$116K ﹤0.01% 2865
2022
Q1 		$311K Buy
18,373
+1,054
+6% +$18K ﹤0.01% 2632
2021
Q4 		$372K Sell
17,319
-302
-2% -$13K ﹤0.01% 2628
2021
Q3 		$1.3M Buy
17,621
+1,415
+9% +$94.3K ﹤0.01% 2111
2021
Q2 		$886K Sell
16,206
-2,069
-11% -$124K ﹤0.01% 2298
2021
Q1 		$1.35M Buy
18,275
+7,311
+67% +$575K ﹤0.01% 2071
2020
Q4 		$945K Buy
10,964
+2,727
+33% +$164K ﹤0.01% 2157
2020
Q3 		$311K Buy
+8,237
New +$324K ﹤0.01% 2505

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RhumbLine Advisers's ALXO Position: Q2 2025 in Review

RhumbLine Advisers sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 46,302 shares — an estimated $28.8K sold.

RhumbLine Advisers first reported a position in ALXO in Q3 2020 and held it in 19 quarters. The position peaked at $1.35M in Q1 2021. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

  • RhumbLine Advisers reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 46,302 ALX Oncology shares in Q2 2025, an estimated $28.8K.
  • RhumbLine Advisers first reported a position in ALX Oncology in Q3 2020 and held it in 19 quarters.
  • RhumbLine Advisers's ALX Oncology position peaked at $1.35M in Q1 2021.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.